| Description |
1 online resource |
| Contents |
Cover; Science, the State, and the City: Britain's Struggle to Succeed in Biotechnology; Copyright; Acknowledgements; Contents; List of Figures; List of Tables; 1: A New Way of Making Medicines; Innovation Ecosystems and Industrial Success; Beyond Biotechnology; The Scientific Breakthroughs behind Biotechnology; The Pharmaceutical Industry and Biotechnology; Definitions and Scope; Structure of the Book; 2: The US Takes the Lead; The First Biotechnology Firms; Investor Attitudes; The Management Challenge; The Emergence of Clusters; Support from Government |
|
Changing Relationships with Big PharmaThe Genomics Bubble and its Aftermath; The Revival of Investor Support; The US Biotech Sector in 2015; Sources of US Strength in Biotech; 3: The British Response; The Creation of Celltech; The Growth of Venture Capital; New Entrants in Biotech; The Stock Market Opens Up; The Introduction of AIM; New Sources of Capital; The Universities Join In; Blows to Confidence; First Steps Towards Consolidation; UK Biotech at the End of the 1990s; 4: Investors Retreat; A Short-lived Boom; Capital Availability; The Government Intervenes; Looking for Beacons |
|
A Potential Star: Cambridge Antibody TechnologyDe-risking Strategies; The London IPO Market; The Lure of the US; Benefits of a US Connection; Trade Sales Continue; Selling out Too Soon?; Onset of the World Financial Crisis; Could the Government Help?; 5: A Second Chance for UK Biotech; More Casualties; Venture Capitalists Look for Quicker Exits; Still Looking for Beacons; New Sources of Finance; Business Angels: The Avidex Story; London Stock Exchange versus NASDAQ; British Institutional Investors; The London Market Opens Up; The Unquoted Firms; The UK Biotech Sector in 2015 |
|
6: Learning from the US An International Comparison; Japan; Germany; France; Switzerland; Weaknesses in National Innovation Ecosystems; 7: The Financing of Biotech; The Changing Funding Environment; Underfunding; Were the Best Firms Sold Too Early?; A Patient, Long-term Investor; The Enduring Appeal of NASDAQ; The Role of AIM; The Missing Tier in UK Biotech; 8: The Role of Government; British Success in Pharmaceuticals; What was Special about Biotechnology?; Biotechnology Policy under Conservative Governments, 1979-1997; Continuity under New Labour; The Return of Industrial Policy |
|
The Government's Changing Contribution to BiotechThe Limits of Industrial Policy; 9: The Persistence of Industrial Leadership; The US Innovation Ecosystem; What Held Other Countries Back?; The Future of the Biotech Sector; Bibliography; Index |
| Summary |
This work examines the evolution of one of the most important technologies that has emerged in the last 50 years: biotechnology - the use of living organisms, or parts thereof to create useful products and services. It explains how firms based in the US took the lead in commercialising the technology, and why it has been so difficult for firms in other countries to match what the leading American companies have achieved |
| Bibliography |
Includes bibliographical references and index |
| Subject |
Biotechnology industries -- Great Britain
|
|
Biotechnology -- Great Britain
|
|
Physical sciences.
|
|
Bioengineering.
|
|
Biotechnology.
|
|
Cities and towns.
|
|
Life sciences.
|
|
Ecological and Environmental Phenomena
|
|
Natural Science Disciplines
|
|
Disciplines and Occupations
|
|
Biological Phenomena
|
|
Phenomena and Processes
|
|
Biotechnology
|
|
Cities
|
|
Biological Science Disciplines
|
|
Environment
|
|
physical sciences.
|
|
bioengineering.
|
|
cities.
|
|
biological sciences.
|
|
Physical sciences
|
|
Life sciences
|
|
Cities and towns
|
|
Bioengineering
|
|
Biotechnology
|
|
Biotechnology industries
|
|
Great Britain
|
| Form |
Electronic book
|
| Author |
Hopkins, Michael M., author
|
| ISBN |
9780191794308 |
|
0191794309 |
|
0191043885 |
|
9780191043888 |
|
